Hyaluronic acid (HA), or Hyaluronan, is an acidic glycosaminoglycan that is widely present in the extracellular matrix of human tissues, such as the vitreous humor of the eye, synovial fluid of joints, and other connective tissues. As a gel-like substance, it restricts the diffusion of water and other extracellular materials, thereby limiting the mobility of subcutaneous fluids. Hyaluronoglucosaminidase (hyaluronidase) (EC 3.2.1.35), abbreviated as HAase, is an endoglycosidase that can break down hyaluronic acid. It hydrolyzes the β-1,4 glycosidic bonds within HA polymer molecules, producing small molecular HA or oligosaccharides, thereby increasing tissue permeability and fluid infiltration. In clinical field, hyaluronidase can be used as a drug permeation enhancer, anesthetic adjuvant, or postoperative edema-relieving agent. It promotes the diffusion of locally accumulated drug solutions, exudates, or blood, accelerates drug absorption, reduces local tissue tension and pain, and aids in the absorption and dissipation of edema and inflammatory exudates.

Ricefidase is a novel IgG-degrading enzyme derived from a non-human pathogen S. equi ssp. equi. It works through a unique and efficient mechanism to rapidly break down pathogenic “bad antibodies”，thus effectively alleviating the symptoms of related diseases. It has a wide range of applications, including the treatment of acute and severe autoimmune diseases, and the effective elimination of neutralizing antibodies in gene therapy.
Ricefidase efficiently cleaves IgG into F(ab’)2 and Fc fragments, with its pharmacological effects manifesting within one hour of administration. This product is independently developed by Bao Pharma and has a global patent portfolio. Ricefidase has completed Phase I clinical trials with positive results in both New Zealand and China, and is currently undergoing Phase II/III trials.
Additionally, Ricefidase has received FDA approval for clinical trials aimed at treating a broad spectrum of autoimmune diseases triggered by pathogenic IgG. Extensive clinical trials have demonstrated that Ricefidase is safe and well-tolerated, with rapid and complete degradation of IgG achievable as the dosage increases.

Chymotrypsin is a protease that rapidly breaks down proteins, liquefies pus, and necrotic tissue. It has been in clinical use for over 50 years and is widely applied in nearly 20 medical departments, including respiratory medicine, surgery, otorhinolaryngology, gynecology and obstetrics, pediatrics, dentistry, ophthalmology, dermatology, gastroenterology, and proctology.
Currently available domestic drugs are extracted from bovine or porcine pancreas, leading to widespread concerns about the biosafety risks associated with animal-derived drugs. Bao Pharma has pioneered the use of a yeast expression system to produce medicinal recombinant human chymotrypsin as a replacement for animal-derived products. This method yields high-purity proteins, which are non-allergenic, and offers a wide range of raw material sources at low cost, with enhanced safety and reliability. The production of non-animal and plasma-free biologics to replace products extracted from animal tissues represents the future trend in upgrading biochemical extraction drugs.

KJ015 is a bispecific anti-HER2 antibody independently designed by Bao Pharma, derived from common light chain technology. Due to its ability to maintain high affinity for two epitopes simultaneously, KJ015 clusters with the antigen on the cell membrane surface, demonstrating characteristics significantly superior to combination monoclonal antibodies in HER2-positive tumors. The lead indication validated in preclinical studies is gastroesophageal adenocarcinoma, and it also shows promise in treating other cancers such as cholangiocarcinoma, gallbladder cancer, parotid gland cancer, endometrial cancer, ovarian cancer, and colorectal cancer. This makes KJ015 particularly promising for clinical outcomes in HER2 high-expression and moderate-expression malignant tumors. Moreover, even in HER2-positive breast cancer, KJ015 exhibits pharmacodynamic properties that give it a competitive edge.

The symmetrical molecular design of KJ015 ensures high stability, high expression levels, and a simple, cost-effective production process. When combined with the company’s independently developed hyaluronidase, KJ015 further leverages the clinical advantages of safe and convenient subcutaneous administration, making it highly competitive in the market.